When applied to predict other immunotherapies on different tumors, including PD1/PD-L1 suppressor against metastatic UCs and MAGE−A3 responses to metastatic melanoma, ELISE also performed outstandingly, which could be evidenced by our findings in Figure 6. This evidence concerns the gene CD274 and metastatic melanoma.